-
The annual scientific sessions of the American Heart Association (AHA; Dallas) primarily feature broad platforms for new product rollouts, an avalanche of clinical trials and even, occasionally, some interesting debate.
-
CryoCath Technologies (Montreal), a company developing cryotherapy products to treat cardiovascular disease, reported that its Freezor MAX catheter has received a supplemental premarket approval (PMA) indication from the FDA, allowing it to launch its fifth product into the U.S.
-
-
-
-
Eric Topol, MD, chief academic officer of the Cleveland Clinic, said during the Clinic-sponsored Medical Innovation Summit here in mid-October that those involved with or interested in innovation need to get away from the idea that every drug and device needs to be a blockbuster product.
-
E-Z-EM (Lake Success, New York) reported that the spin-off of its AngioDynamics subsidiary has been completed. On Oct. 30, E-Z-EM distributed 0.856377 of a share of AngioDynamics common stock as a dividend on each outstanding share of E-Z-EM common stock to E-Z-EM shareholders of record as of Oct. 11. E-Z-EM shareholders received cash in lieu of any fractional shares.
-
Arrow International (Reading, Pennsylvania) reported the promotion of several executives to positions of new responsibility and the retirement of Philip Fleck, president and chief operating officer, effective Dec. 31.
-
American women are one step closer to having a contraceptive implant option with the recent Food and Drug Administration (FDA) issuance of approvable status for Implanon, the single-rod contraceptive implant from Organon (West Orange, NJ).
-
You suspect that your 17-year-old patient may have a chlamydia infection. Thanks to a nucleic acid amplification screen on a urine specimen, you are able to detect the sexually transmitted disease (STD) and report the results the next day.